-
Price Momentum
EOCN is trading near the bottom of its 52-week range and below its 200-day simple moving average.
-
Price change
The price of EOCN shares has increased $0.13 since the market last closed. This is a 3.86% rise.
-
Last closed at $3.50.
The stock has since risen $0.13 in pre-market trading.
Key terms
About EOCN
Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
-
Market cap: $3.65M
A market capitalization up to $300 million places EOCN in the micro-capitalization category.
Key terms
Smart score
Latest EOCN news
No recent press releases are available for EOCN
EOCN Financials
-
EOCN total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.
-
Net income: -$10.31M (1Y), -$2.72M (Q2)
Net Income decreased 37.14% since last year and decreased 42.57% since last quarter.
-
Earnings per share: -$19.13 (1Y), -$2.86 (Q2)
EPS increased 70.39% since last year and decreased 23.36% since last quarter.
Key terms
EOCN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EOCN Competitors
-
How competitors are chosen
EOCN's competitors are included in the Health Technology sector and Pharmaceuticals: Major group
-
Market cap: $3.65M
A market capitalization up to $300 million places EOCN in the micro-capitalization category.
